Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of CT-P27 in Acute Uncomplicated Influenza A Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female subjects between the ages of 19 and 64 years, both inclusive~* Diagnosed with influenza A at screening using rapid influenza diagnostic test~* Onset of influenza symptoms and fever is within 48 hours at screening~* At least 2 of symptoms (moderate to severe in intensity)~* ≥38.0'C body temperature at screening~Exclusion Criteria:~* Taking antiviral treatment for influenza or has a history of using these antivirals within 14 days prior to the administration of study drug~* Positive influenza B or A+B infection

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- CT-P27 90 mg/kg (Type: EXPERIMENTAL): CT-P27 will be administrated once in IV infusion.
- CT-P27 45mg/kg (Type: EXPERIMENTAL): CT-P27 will be administrated once in IV infusion.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administrated once in IV infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).